Date: 2014-12-22
Type of information: R&D agreement
Compound: novel antibiotics
Company: Genentech, a member of Roche Group (USA - CA - Switzerland) Phylogica (Australia)
Therapeutic area: Infectious diseases
Type agreement: R&D licensing
Action mechanism: Phylogica’s proprietary Phylomer® libraries contain billions of distinct peptides. The Phylomer® libraries are based on expressed sequences of protein fragments that are encoded by the natural genes of evolutionary diverse microbes that often exist in extreme environments. Typically, these peptides, which are known as Phylomer® peptides, are comprised of 15 to 50 amino acids. The Phylomer® peptide sequences were sourced from an evolutionary diverse range of microbes (Bacteria and Archaea) genomes. These microbes were often collected from diverse and harsh environments, where their genomes were subject to intense natural selection to evolve the most stable protein structures that facilitated their survival.
Disease: bacterial infections
Details: * On December 22, 2014, Phylogica, a public Australian drug discovery company, announced that it has extended its collaboration with Genentech, a member of the Roche Group, by entering into a Research and Licensing agreement to discover novel antibiotics. Phylogica will employ its Phylomer® drug discovery platform, including its proprietary cellpenetrating peptide discovery technology to identify Phylomer peptides suitable for further evaluation.
Financial terms: Under the terms of the agreement, Phylogica will receive an upfront payment of US$500,000. In addition, Phylogica is eligible to receive research, development, and commercialization milestone payments totaling up to US$142 million.
Latest news:
